HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.

AbstractBACKGROUND:
The survival benefit of a strategy of coronary-artery bypass grafting (CABG) added to guideline-directed medical therapy, as compared with medical therapy alone, in patients with coronary artery disease, heart failure, and severe left ventricular systolic dysfunction remains unclear.
METHODS:
From July 2002 to May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to undergo CABG plus medical therapy (CABG group, 610 patients) or medical therapy alone (medical-therapy group, 602 patients). The primary outcome was death from any cause. Major secondary outcomes included death from cardiovascular causes and death from any cause or hospitalization for cardiovascular causes. The median duration of follow-up, including the current extended-follow-up study, was 9.8 years.
RESULTS:
A primary outcome event occurred in 359 patients (58.9%) in the CABG group and in 398 patients (66.1%) in the medical-therapy group (hazard ratio with CABG vs. medical therapy, 0.84; 95% confidence interval [CI], 0.73 to 0.97; P=0.02 by log-rank test). A total of 247 patients (40.5%) in the CABG group and 297 patients (49.3%) in the medical-therapy group died from cardiovascular causes (hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006 by log-rank test). Death from any cause or hospitalization for cardiovascular causes occurred in 467 patients (76.6%) in the CABG group and in 524 patients (87.0%) in the medical-therapy group (hazard ratio, 0.72; 95% CI, 0.64 to 0.82; P<0.001 by log-rank test).
CONCLUSIONS:
In a cohort of patients with ischemic cardiomyopathy, the rates of death from any cause, death from cardiovascular causes, and death from any cause or hospitalization for cardiovascular causes were significantly lower over 10 years among patients who underwent CABG in addition to receiving medical therapy than among those who received medical therapy alone. (Funded by the National Institutes of Health; STICH [and STICHES] ClinicalTrials.gov number, NCT00023595.).
AuthorsEric J Velazquez, Kerry L Lee, Robert H Jones, Hussein R Al-Khalidi, James A Hill, Julio A Panza, Robert E Michler, Robert O Bonow, Torsten Doenst, Mark C Petrie, Jae K Oh, Lilin She, Vanessa L Moore, Patrice Desvigne-Nickens, George Sopko, Jean L Rouleau, STICHES Investigators
JournalThe New England journal of medicine (N Engl J Med) Vol. 374 Issue 16 Pg. 1511-20 (Apr 21 2016) ISSN: 1533-4406 [Electronic] United States
PMID27040723 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Topics
  • Aged
  • Cardiovascular Diseases (mortality)
  • Cause of Death
  • Combined Modality Therapy
  • Coronary Artery Bypass
  • Female
  • Follow-Up Studies
  • Heart Failure (surgery)
  • Hospitalization (statistics & numerical data)
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Myocardial Ischemia (drug therapy, surgery)
  • Stroke Volume
  • Ventricular Dysfunction, Left (surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: